Description
SWOT ANALYSIS OF SUN PHARMA INDUSTRIES
Sun Pharma Industries
Parent Company
Sun Pharma Industries
Category
Pharmaceutical
Sector
Healthcare
Tagline/ Slogan
Leadership through focused research
USP
Sun pharma fifth largest & most profitable company in India
STP
Segment
Cardiology, psychiatry, neurology, gastroenterology, dibetology
Target Group
Healthcare professionals, pharmacists
They are international specialty pharma company with strong presence Positioning in Indian & US generics market
SWOT Analysis
1. Strong growth in emerging market business 2. Introduction of Pantoprazole & Eloxatin in US market has very limited competition 3. They have strong marketing & sales force of over 12,000 employees 4. They have successfully acquired Taro pharma which has further consolidated their position in Indian markets Strength 5. Strong brand presence in India and US markets
1. Stiff competition from many Indian and other global brands means limited market share growth Weakness 2. Limited presence in emerging markets and European countries
1. They can leverage their acquisitions to further increase the growth 2. They can increase their presence in contract manufacturing Opportunity 3. Increasing healthcare awareness in India
1. There is growing competition in generics market Threats 2. Stringent patent regulations
3. High price sensitivity of consumers
Competition
1. Cipla 2. Lupin pharmaceuticals 3. Ranbaxy Competitors 4. Dr. Reddy’s laboratories
doc_425727821.docx
SWOT ANALYSIS OF SUN PHARMA INDUSTRIES
Sun Pharma Industries
Parent Company
Sun Pharma Industries
Category
Pharmaceutical
Sector
Healthcare
Tagline/ Slogan
Leadership through focused research
USP
Sun pharma fifth largest & most profitable company in India
STP
Segment
Cardiology, psychiatry, neurology, gastroenterology, dibetology
Target Group
Healthcare professionals, pharmacists
They are international specialty pharma company with strong presence Positioning in Indian & US generics market
SWOT Analysis
1. Strong growth in emerging market business 2. Introduction of Pantoprazole & Eloxatin in US market has very limited competition 3. They have strong marketing & sales force of over 12,000 employees 4. They have successfully acquired Taro pharma which has further consolidated their position in Indian markets Strength 5. Strong brand presence in India and US markets
1. Stiff competition from many Indian and other global brands means limited market share growth Weakness 2. Limited presence in emerging markets and European countries
1. They can leverage their acquisitions to further increase the growth 2. They can increase their presence in contract manufacturing Opportunity 3. Increasing healthcare awareness in India
1. There is growing competition in generics market Threats 2. Stringent patent regulations
3. High price sensitivity of consumers
Competition
1. Cipla 2. Lupin pharmaceuticals 3. Ranbaxy Competitors 4. Dr. Reddy’s laboratories
doc_425727821.docx